SAN FRANCISCO--(BUSINESS WIRE)--The biotech industry’s report card for the first half of the year contains surprisingly good grades for its performance on the capital markets, and for partnering and venture capital deal making, but all other forms of financing didn’t fare as well, particularly IPOs, the new monthly Burrill Biotechnology Report finds.
